[Form 4] PUMA BIOTECHNOLOGY INC Insider Trading Activity

Rhea-AI Filing Summary

Puma Biotechnology, Inc. (PBYI) Form 4 filing: Senior Vice President of Regulatory Affairs Douglas M. Hunt disclosed two open-market sales executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on 12-14-2020.

• 07/08/2025: Sold 4,374 common shares at $3.533; post-sale holding 168,337 shares.
• 07/09/2025: Sold 3,443 common shares at $3.535; post-sale holding 164,894 shares.

The transactions total 7,817 shares (~4.6% of his reported direct ownership) and were filed by one reporting person. No derivative transactions were reported. Hunt remains an officer of the company.

Positive

• Executive retains a substantial holding of 164,894 common shares after the transactions.
• Sales executed under a pre-arranged Rule 10b5-1(c) plan, suggesting they were scheduled and not based on new information.

Negative

• Insider selling of 7,817 shares may be perceived negatively by some investors despite its small size.

Insights

Financial Analyst

TL;DR – Minor insider sale (7.8k shares) under 10b5-1 plan; limited market impact.

The filing shows modest sales by a senior executive, representing a small fraction of his stake and executed pursuant to a long-standing 10b5-1 plan. Because the sales appear scheduled and the executive still owns more than 160k shares, the activity is best viewed as routine portfolio diversification rather than a signal of changing fundamentals. No options were exercised and no new derivatives were created, keeping overall insider exposure largely intact. Consequently, the disclosure is neutral for investors and unlikely to materially influence valuation or sentiment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HUNT DOUGLAS M

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BLVD., SUITE 2150

(Street)

LOS ANGELES CA 90024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2025		S(1)		4,374	D	$3.533	168,337	D
Common Stock	07/09/2025		S(1)		3,443	D	$3.535	164,894	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Adoption date of referenced 10b5-1(c) plan is: 12-14-2020

Remarks:

The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.

	/s/ Gordon Esplin as attorney-in-fact for Douglas M. Hunt	07/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Puma Biotechnology (PBYI) shares did Douglas M. Hunt sell?

He sold a total of 7,817 shares across two transactions.

What were the sale prices in the July 2025 transactions?

Shares were sold at $3.533 on 07/08/2025 and $3.535 on 07/09/2025.

How many PBYI shares does the executive still own after the sales?

Douglas M. Hunt owns 164,894 common shares directly after the reported transactions.

Were the insider sales made under a 10b5-1 trading plan?

Yes. The filing states the plan was adopted on 12-14-2020 and the box for Rule 10b5-1(c) was checked.

What is Douglas M. Hunt's role at Puma Biotechnology?

He is the company's Senior Vice President of Regulatory Affairs.